ALKS vs OSCR

ALKS presents a stark dichotomy between financial stability and operational growth. While the deterministic health is strong, evidenced by a Piotroski F-Score of 8/9 and a negligible Debt/Equity ratio of 0.04, the company is suffering from severe earnings contraction (-67% YoY) and negative revenue growth. The stock trades at a significant premium to both its Graham Number ($18.8) and Intrinsic Value ($10.01), suggesting the current price is driven by analyst optimism rather than current fundamentals. Despite a 'strong_buy' analyst consensus, insider selling and a deteriorating forward P/E indicate significant valuation risk.

Oscar Health exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational inefficiency. While the company maintains a low Price-to-Sales ratio (0.48) and steady revenue growth of 17.3%, it continues to struggle with negative profit margins and a consistent failure to meet earnings estimates (0/4 beats in the last year). The recent 60.9% one-month price surge appears disconnected from fundamentals, as the stock now trades above the analyst target price of $16.10. Combined with aggressive insider selling by the CFO and CTO, the risk-reward profile is unfavorable.